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Abstract 
Platelet-derived growth factor receptor β (PDGFRβ) is a transmembrane tyrosine 
kinase receptor and it is upregulated in various malignant tumors. Radiolabeled 
PDGFRβ inhibitors can be a convenient tool for the imaging of tumors overexpressing 
PDGFRβ. In this study, [125I]-1-{5-iodo-2-[5-(2-methoxyethoxy)-1H-
benzo[d]imidazol-1-yl]quinoline-8-yl}piperidin-4-amine ([125I]IIQP) and [125I]-N-3-
iodobenzoyl-1-{2-[5-(2-methoxyethoxy)-1H-benzo[d]imidazol-1-yl]quinolin-8-yl}-
piperidin-4-amine ([125I]IB-IQP) were designed and synthesized, and their potential 
as PDGFRβ imaging agents was evaluated. In cellular uptake experiments, [125I]IIQP 
and [125I]IB-IQP showed higher uptake by PDGFRβ-positive cells than by PDGFRβ-
negative cells, and the uptake in PDGFRβ-positive cells was inhibited by co-culture 
with PDGFRβ ligands. The biodistribution of both radiotracers in normal mice 
exhibited hepatobiliary excretion as the main route. In mice inoculated with BxPC3-
luc (PDGFRβ-positive), the tumor uptake of radioactivity at 1 h after the injection of 
[125I]IIQP was significantly higher than that after the injection of [125I]IB-IQP. These 
results indicated that [125I]IIQP can be a suitable PDGFRβ imaging agent. However, 
further modification of its structure will be required to obtain a more appropriate 
PDGFRβ-targeted imaging agent with a higher signal / noise ratio. 
Keywords: radiotracer, molecular imaging, PDGFRβ, tyrosine kinase inhibitor 
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1. Introduction 
PDGFRβ belongs to a subfamily of receptor tyrosine kinases (RTKs). It 
possesses an outer membrane with a PDGF ligand binding site and an inner membrane 
tyrosine kinase (TK) domain with an adenosine triphosphate (ATP) binding site.1 
Binding of PDGF ligands to the extracellular binding domain triggers PDGFRβ 
dimerization, thus inducing phosphorylation of its intracellular regions due to an 
activated ATP-binding domain. This is followed by the activation of signaling 
pathways that regulate important cellular functions.2 The expression of PDGFRβ is 
highly restricted in most normal cells; however, upregulation of PDGFRβ in 
numerous human tumors and its relationship with tumor progression features such as 
cell migration, metastasis, angiogenesis, and proliferation, have been reported.3-5 
Therefore, PDGFRβ can be an attractive target not only for cancer therapy but also 
for developing tumor-imaging agents.6-8 
Nuclear medicine has been a revolutionary invention in the field of diagnostic 
imaging because it is noninvasive and facilitates continuous monitoring of disease 
progression or treatment response.9,10 Moreover, the imaging modalities in nuclear 
medicine, such as single photon emission computed tomography (SPECT) and 
positron emission tomography (PET) can quantify receptor density and molecular 
target expression in patients, thus becoming a useful tool in drug development.10-12 
Previous studies have reported imaging agents, including radiolabeled protein,13,14 
aptamer,15 affibody molecules,16,17 and peptide18,19 that target the extracellular parts 
of PDGFRβ. Although the imaging of intracellular parts of PDGFRβ, particularly its 
ATP-binding site, has hardly been reported,8 the ATP-binding is very important for 
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following signal transductions and growth of cancer cells. Therefore, the ATP-
binding site can be a target for TK inhibitors (TKIs). Meanwhile, mutations of the 
ATP-binding site have frequently been found20,21. The mutation status often affects 
therapeutic effects of TKIs. Thus, the information of the ATP-binding site, containing 
the mutation status, is useful for the prediction of therapeutic effects of TKIs. Other 
radiolabeled TK inhibitors (TKIs)22-26 and their potential advantages, such as 
assessment of drug sensitivity20, mutation status21, and usefulness in drug 
screening11,27,28 have been demonstrated. 
1-{2-[5-(2-Methoxyethoxy)-1H-benzo[d]imidazol-1-yl]quinolin-8-
yl}piperidin-4-amine (CP-673451, IQP) (Figure 1) is a highly selective 
benzimidazole inhibitor of PDGFRβ (IC50 = 1 nM) over PDGFRα (IC50 = 10 nM). 
Importantly, it is 1,000 times selective compared with many other RTKs. It 
competitively inhibits ATP-binding to the ATP-binding site of PDGFRβ and blocks 
phosphorylation.29,30 High binding affinity and high selectivity to the molecular target 
are important for a lead compound of imaging probes. IQP can be an attractive 
compound in an attempt to image the ATP binding site of PDGFRβ. Therefore, we 
speculated that radiolabeled IQP derivatives that bind the ATP-binding site may be 
useful imaging probes. 
To develop novel radiolabeled molecular probes for PDGFRβ imaging, we chose 
radioiodine as a radionuclide in this study because 123I (t1/2 = 13.2 h) and 124I (t1/2 = 
4.2 d) are useful radionuclides for SPECT and PET, respectively. We did not have 
sufficient information about the introduction of radioiodine into IQP structure to 
retain high affinity for PDGFRβ. To evaluate the feasibility of IQP derivatives as 
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PDGFRβ imaging probes, we designed and synthesized two different types of iodine 
labeled IQP, 1-{5-iodo-2-[5-(2-methoxyethoxy)-1H-benzo[d]imidazol-1-
yl]quinolin-8-yl}piperidin-4-amine (IIQP) and N-3-iodobenzoyl-1-{2-[5-(2-
methoxyethoxy)-1H-benzo[d]imidazol-1-yl]-quinolin-8-yl}-piperidin-4-amine (IB-
IQP). In IIQP, iodine was directly introduced to C-5 of the quinoline group of IQP 
because it is a reactive site for halogenation of IQP. In IB-IQP, iodine was indirectly 
introduced by conjugation of 3-iodo benzoyl group using SIB (N-succinimidyl-3-
iodobenzoate) with the primary amine group of IQP. We then examined the binding 
affinities of two derivatives for PDGFRβs. Subsequently, radiotracers [125I]IIQP and 
[125I]IB-IQP (Figure 1) were synthesized and evaluated in vitro and in vivo to 
investigate their usefulness as PDGFRβ imaging agents. Although we are interested 
in developing imaging probes for SPECT and PET, 125I was used as an alternative 
radionuclide in these initial studies because of its long half-life (t1/2 = 59.4 d). 
 
Figure 1. Chemical structures of IQP, [125I]IIQP, and [125I]IB-IQP. 
 
 
2. Material and methods 
2.1. General 
Commercial reagents and solvents were purchased from Sigma-Aldrich (St. 
Louis, MO, USA), Wako Pure Chemical Industries (Osaka, Japan), Nacalai Tesque, 
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Inc., (Kyoto, Japan), Tokyo Chemical Industry, Co., Ltd., (Tokyo, Japan) and Kanto 
Chemical, Co., Inc. (Tokyo, Japan) and used without further purification unless 
otherwise stated. 
[125I]Sodium iodide (644 GBq/mg) was purchased from Perkin Elmer (Waltham, 
MA, USA). The radioactivity was measured by an Auto Gamma System ARC-7010B 
(Hitachi, Ltd., Tokyo, Japan).  
Bicinchoninic Acid (BCA) Protein Assay Kit and Cell Counting Kit (CCK) were 
purchased from Nacalai Tesque, Inc. and Dojindo (Kumamoto, Japan), respectively. 
Recombinant murine platelet-derived growth factor-BB (PDGF-BB) was purchased 
from PeproTech (Rocky Hill, NJ, USA). TR-PCT1 rodent brain pericyte cell line was 
a generous gift from Dr. Emi Nakashima (Keio University, Tokyo, Japan),31 MCF7 
breast cancer cell lines were purchased from DS Pharma Biomedical (Osaka, Japan), 
and BxPC3-luc pancreatic cell line was purchased from JCRB Cell Bank (Ibaraki, 
Japan). 
Proton and carbon nuclear magnetic resonance (1H-NMR and 13C-NMR) spectra 
were obtained with JEOL JNM-ECS400 (JEOL Ltd, Tokyo, Japan). Direct analysis 
in real time mass spectra (DART-MS) and Electrospray ionization mass spectra (ESI-
MS) were obtained with JEOL JMS-T100TD (JEOL Ltd). Purification were 
conducted using reversed-phase high-performance liquid chromatography (RP-
HPLC) system. TLC analysis were performed with silica plates (Art 5553, Merck, 
Darmstadt, Germany). Optical density in WST-8 assay was obtained using Infinite® 
F200 Pro microplate reader (TECAN, Männedorf, Switzerland). 
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2.2. Synthesis of reference compounds and precursors  
Intermediate and reference compounds, IQP, ATE, and SIB, were synthesized 
according to the reported studies, with a slight modification.32-37 Detailed procedures 
were shown in the Supporting Information. 
 
2.2.1. 1-{5-Iodo-2-[5-(2-methoxyethoxy)-1H-benzo[d]imidazol-1-
yl]quinolin-8-yl}piperidin-4-amine (IIQP) (13) 
A mixture of N-chlorosuccinimide (NCS) (80 mg, 0.6 mmol, 1.2 eq.) and sodium 
iodide (NaI) (90 mg, 0.6 mmol, 1.2 eq.) in acetic acid (5 mL) was added to 12 (209 
mg, 0.5 mmol, 1.0 eq.) in acetic acid (5 mL) and the mixture was stirred at 50 °C for 
18 h under nitrogen atmosphere. After adjusting pH to 9.0 using saturated aqueous 
sodium bicarbonate (NaHCO3), the reaction mixture was extracted with 
dichloromethane (3 x 30 mL). The organic layer was dried over sodium sulfate, 
filtered, and concentrated under reduced pressure. The crude product was purified by 
column chromatography on silica gel (chloroform/methanol = 50/1) to afford 13 (217 
mg, 80%) as a pale yellow solid. 1H NMR (400 MHz, CDCl3): δ 1.76 – 1.85 (2H, m), 
2.01 – 2.10 (2H, m), 2.85 – 2.96 (3H, m), 3.50 (3H, s), 3.82 – 3.84 (2H, m), 3.99 (2H, 
br d), 4.23 – 4.25 (2H, m), 7.00 (1H, d, J = 8.0 Hz), 7.26 (1H, dd, J = 11.2, 2.0 Hz), 
7.38 (1H, d, J = 2.0 Hz), 7.74 (1H, d, J = 9.2 Hz), 7.98 (1H, d, J = 8.0 Hz), 8.39 (1H, 
d, J = 9.2 Hz), 8.56 (1H, d, J = 9.2 Hz), 8.68 (1H, s). 13C NMR (100 MHz, CDCl3): δ 
156.05, 150.46, 147.08, 145.51, 144.70, 142.19, 141.34, 137.42, 129.16, 126.68, 
119.56, 114.91, 114.35, 113.68, 103.52, 88.63, 71.08, 67.77, 59.26, 51.44 (2C), 48.73, 
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36.28 (2C). HRMS (ESI+) calcd for C24H27IN5O2 [M+H+]: m/z = 544.1204, found 
544.1166. 
  
Scheme 1. Synthesis of reference compound IQP (a) sodium tungstate dihydrate, hydrogen 
peroxide, 75 °C, 5 h (b) acetic anhydrate, 100 °C, 7.5 h (c) HCl, 95 °C, 2 h (d) benzyl bromide, 
potassium carbonate, reflux, 6 h (e) POCl3, reflux, 16 h (f) cesium carbonate, reflux, 3 d (g) 
palladium acetate, DIPHOS, cesium carbonate, phenyl boronic acid, 115 °C, 3 d (h) (i) palladium 
chloride, TEA, formic acid, 65 °C, 2 h (ii) formamidine acetate, reflux, overnight (i) N-phenyl-
bis(trifluoromethanesulfonimide), room temperature, 2 d (j) cesium carbonate, rac-BINAP, 




A mixture of 13 (100 mg, 0.2 mmol, 1.0 eq.), triethylamine (TEA) (56 µL, 0.4 
mmol, 2.0 eq.) and di-tert-butyl dicarbonate (Boc2O) (109 mg, 0.5 mmol, 2.5 eq.) in 
dry dichloromethane (2 mL) was stirred at room temperature for 3 days under nitrogen 
atmosphere. The reaction mixture was diluted with dichloromethane and washed 
successively with saturated aqueous NaHCO3 and brine. The organic layer was dried 
over sodium sulfate, filtered, and concentrated under reduced pressure to afford 14 
(100 mg) as a pale yellow solid. The product was used in the following reaction 
without further purification. 





A mixture of 14 (47 mg, 72.3 µmol, 1.0 eq.), hexabutyldistannane (73 µL, 144.6 
µmol, 2.0 eq.), and tetrakis(triphenylphosphine)palladium(0) Pd[P(C6H5)3]4 (4 mg, 
3.6 µmol, 5% eq.) in dry toluene (2 mL) was refluxed for 24 h under nitrogen 
atmosphere. After removing the catalyst by filtration through a pad of Celite® and 
washing with toluene, the filtrate was concentrated under reduced pressure and 
purified by HPLC with mobile phase system methanol (A) (with 0.05% TEA) and 
water (B) (with 0.05% TEA), A : 97.5 – 100%, 20 min using 5C18 MSII (10ID x 250 
mm) column, flow rate 4 mL/min, to afford 15 (28 mg, 48%) as a pale yellow solid. 
1H NMR (400 MHz, DMSO-d6): δ 0.82 – 0.86 (9H, m), 1.11 – 1.21 (6H, m), 1.26 – 
1.35 (6H, m), 1.43 (9H, s), 1.47 – 1.59 (6 H, m), 1.83 – 1.88 (4H, m), 2.74 – 2.79 (2H, 
m), 3.35 (3H, s), 3.46 (1H, br s), 3.72 – 3.74 (2H, m), 3.78 (2H, br d), 4.19 – 4.21 (2H, 
m), 7.32 (1H, d, J = 7.2 Hz), 7.34 (1H, s), 7.38 (1H, d, J = 8.8 Hz), 7.57 (1H, d, J = 
7.6 Hz), 8.17 – 8.23 (2H, m), 8.93 (1H, d, J = 8.8 Hz), 9.16 (1H, s). 13C NMR (100 
MHz, CDCl3): δ 155.66, 154.99, 149.57, 146.49, 145.02, 142.18, 141.49, 141.45, 
135.50, 134.54, 132.47, 126.25, 118.10, 116.49, 114.49, 112.23, 102.50, 77.51, 70.53, 
67.21, 58.19, 51.30 (2C), 47.61, 32.67 (2C), 28.69 (3C), 28.32 (3C), 26.66 (3C), 13.52 
(3C), 10.01 (3C). HRMS (ESI+), calcd for C41H62N5O4Sn [M+H+]: m/z = 808.3818, 
found 808.3846. 
 
Effendi el al. 11/35 
2.2.4. N-3-iodobenzoyl-1-{2-[5-(2-methoxyethoxy)-1H-
benzo[d]imidazol-1-yl]-quinolin-8-yl}-piperidin-4-amine (IB-IQP) (18) 
A mixture of 12 (12 mg, 30.0 µmol, 1.0 eq.), N,N-diisopropylethylamine 
(DIPEA) (6 µL, 33.0 µmol, 1.1 eq.), and 17 (11 mg, 33.0 µmol, 1.1 eq.) in dry 
dichloromethane (1 mL) was stirred at 50 °C for 2 h under nitrogen atmosphere. After 
completion of the reaction, the reaction mixture was diluted with dichloromethane 
and washed with water. The organic layer was dried over sodium sulfate, filtered, and 
concentrated under reduced pressure. The crude product was purified by column 
chromatography on silica gel (chloroform/methanol = 100/1) to afford 18 (15 mg, 
77%) as a colorless solid. 1H-NMR (400 MHz, DMSO-d6): δ 2.01 – 2.06 (4H, m), 
2.86 – 2.91 (2H, m), 3.32 (3H, s), 3.71 – 3.73 (2H, m), 3.87 (2H, br d), 4.02 (1H, br 
s), 4.19 – 4.21 (2H, m), 7.31 – 7.38 (4H, m), 7.52 (1H, t, J = 8.0 Hz), 7.65 (1H, d, J 
= 8.4 Hz), 7.92 (2H, t, J = 8.0 Hz), 8.19 (1H, d, J = 8.8 Hz), 8.24 (1H, s), 8.56 (1H, d, 
J = 8.4 Hz), 8.64 (1H, d, J = 8.0 Hz), 8.95 (1H, d, J = 8.8 Hz), 9.19 (1H, s). 13C NMR 
(100 MHz, CDCl3): δ 164.41, 155.56, 149.04, 146.97, 145.08, 142.42, 140.50, 140.34, 
139.66, 136.95, 135.67, 130.48, 127.34, 126.97, 126.40, 126.31, 121.63, 118.35, 
116.37, 114.21, 112.45, 102.76, 94.65, 70.52, 67.26, 58.22, 51.40 (2C), 47.18, 32.11 





Effendi el al. 12/35 
The mixture of 12 (27 mg, 73.0 µmol, 1.0 eq.), DIPEA (15 µL, 80.0 µmol, 1.1 
eq.), and 16 (40 mg, 80.0 µmol, 1.1 eq.) in dry dichloromethane (3 mL) was stirred at 
50 °C for 3 h under nitrogen atmosphere. After completion of the reaction, the reaction 
mixture was diluted with dichloromethane and washed with water. The organic layer 
was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The 
crude product purified by column chromatography on silica gel (chloroform/methanol 
= 100/1) to afford 19 (33 mg, 56%) as a pale yellow solid. 1H-NMR (400 MHz, 
DMSO-d6): δ 0.84 – 0.88 (9H, m), 1.01 – 1.18 (6H, m), 1.26 – 1.35 (6H, m), 1.45 – 
1.60 (6H, m), 2.03 – 2.06 (4H, m), 2.86 – 2.91 (2H, m), 3.31 (3H, s), 3.66 – 3.72 (2H, 
m), 3.88 (2H, br d), 4.03 (1H, br s), 4.17 – 4.18 (2H, m), 7.30 – 7.38 (3H, m), 7.46 
(1H, t, J = 7.2 Hz), 7.52 (1H, t, J = 8.0 Hz), 7.60 (1H, d, J = 7.6 Hz), 7.65 (1H, d, J = 
7.2 Hz), 7.81 (1H, d, J = 8.0 Hz), 7.91 (1H, s), 8.18 (1H, d, J = 9.2 Hz), 8.51 (1H, d, 
J = 7.6 Hz), 8.56 (1H, d, J = 9.2 Hz), 8.92 (1H, d, J = 8.8 Hz), 9.19 (1H, s). 13C NMR 
(100 MHz, DMSO-d6): δ 166.56, 155.56, 149.08, 146.94, 145.12, 142.39, 141.39, 
140.50, 140.31, 138.81, 135.13, 134.47, 127.60, 127.33, 126.94, 126.35, 126.29, 
121.56, 118.27. 116.30, 114.26, 112.43, 102.68, 70.51, 67.21, 58.13, 51.40 (2C), 
47.01, 32.21 (2C), 28.58 (3C), 26.68 (3C), 13.53 (3C), 9.21 (3C). HRMS (ESI+) calcd 
for C43H58N5O3Sn [M+H+]: m/z = 812.3556, found 812.3573). 
 
2.3. Cell viability assays 
TR-PCT1 cells were seeded on 96-well culture plates (5 x 103 cells/well) and 
cultured in DMEM medium containing 2% FBS and 20 ng/mL PDGF-BB at 33 °C in 
a humidified 5% CO2 atmosphere. Cells were treated with each compound for 72 h 
Effendi el al. 13/35 
and cell viability was assessed using the Cell Counting Kit following the 
manufacturer's instructions. Briefly, cells were incubated with WST-8 at 33 °C in a 




Radiotracers, [125I]IIQP and [125I]IB-IQP, were synthesized by an 
iododestannylation reaction of the corresponding tributylstannyl precursors (15 or 19) 
using NCS as an oxidizing agent. The radiotracers were isolated by RP-HPLC using 
a Cosmosil 5C18MSII column (4.6 ID × 150 mm) at the flow rate of 1 mL/min with a 
gradient mobile phase of 70% methanol in water with 0.05% TEA to 90% methanol 
in water with 0.05% TEA for 20 min. The column temperature was maintained at 
40 °C. Radiochemical yield and purity were determined by an auto well gamma 
counter. 
 
2.4.1. Synthesis of [125I]IIQP (20) 
A solution of [125I]NaI in 0.1 M NaOH aqueous solution (non-carrier added, 370 
kBq, 2 µL) was charged into a sealed vial containing 5 (1 mg/mL, 5 µL), acetic acid 
(5%, 30 µL), acetonitrile (55 µL), and NCS (5 mg/mL, 10 µL). The mixture was 
shaken at room temperature for 15 min, quenched by addition of sodium 
hydrogensulfite (5 mg/mL, 10 µL) and the solvent was removed by nitrogen gassing. 
TFA was added to the residue and the shaking was allowed to continue for 30 min. 
After removing TFA by nitrogen gassing, the residue was mixed with initial mobile 
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phase of HPLC. The reaction mixture was shaken for some minutes, filtered, and 
analyzed by HPLC. 
 
Scheme 2. Synthesis of reference compound, precursor, and radioiodinated compound 
[125I]IIQP (a) NCS, NaI, 50 °C, 18 h (b) Boc2O, TEA, room temperature, 3 d (c) hexabutyldistannane, 
Pd[P(C6H5)3]4, reflux, 24 h (d) [125I]NaI, NCS, acetic acid, room temperature, 15 min (e) TFA, room 
temperature, 30 min. 
 
2.4.2. Synthesis of [125I]IB-IQP (21) 
A solution of [125I]NaI in 0.1 M NaOH aqueous solution (non-carrier added, 370 
kBq, 2 µL) was added in a sealed vial containing 19 (1 mg/mL, 5 µL), acetic acid 
(5%, 10 µL), acetonitrile (10 µL), and NCS (5 mg/mL, 15 µL). The mixture was 
shaken at room temperature for 15 min, quenched by addition of sodium 
hydrogensulfite (5 mg/mL, 15 µL) and purified by HPLC. 
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Scheme 3. Synthesis of reference compound, precursor, and radioiodinated compound 
[125I]IB-IQP (a) 50 °C, 2 h; (b) 50 °C, 3 h; (c) [125I]NaI, NCS, acetic acid, room temperature, 15 
min. 
 
2.5. Determination of partition coefficients 
Partition coefficients of [125I]IIQP and [125I]IB-IQP into n-octanol and 0.1 M 
phosphate buffer (PB) pH 7.4 were measured as described previously with a slight 
modification.38 Briefly, [125I]IIQP or [125I]IB-IQP was added to the mixture of n-
octanol (3.0 mL) and PB (3.0 mL) in a test tube. The test tube was vortexed (1 min), 
left at room temperature (10 min), and centrifuged (5 min, 3,060g, 4 °C). n-Octanol 
layer (2.0 mL) was transferred into new test tube followed by addition of fresh n-
octanol (1.0 mL) and PB (3.0 mL). After repeating vortex, standing, and centrifuge, 
radioactivity of each layer, n-octanol (1.0 mL) and PB (1.0 mL), was counted using 
an auto well gamma counter (n = 4). 
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2.6. In vitro stability assay 
The stability of radiotracers, [125I]IIQP and [125I]IB-IQP, were analyzed as 
described previously with a slight modification.39 Briefly, [125I]IIQP or [125I]IB-IQP 
solution (50 µL) in sealed tube containing 0.1 M phosphate buffered saline (PBS) pH 
7.4 (450 µL) was incubated at 37 °C for 1, 3, 6, and 24 h. After incubation, the purities 
of radiotracers were analyzed by TLC using chloroform/methanol = 5/1 and 20/1 for 
[125I]IIQP and [125I]IB-IQP, respectively as a developing solvent and the results were 
confirmed by HPLC. 
 
2.7. Cellular uptake study 
BxPC3-luc or MCF7 cells were cultured in RPMI 1640 medium containing 10% 
FBS and penicillin (100 IU/mL)-streptomycin (100 µg/mL) on 6-well culture plates 
(containing 2 x 105 cells/well) for 24 h using a humidified atmosphere (5% CO2) 
incubator at 37 °C. After removal of medium, a solution of [125I]IIQP or [125I]IB-IQP 
(3.7 kBq/well) in medium without FBS was added. After incubation for 0.5, 1, 2, and 
4 h, the medium from each well was removed and the cells were washed once with 
ice-cold PBS (1 mL). The cells were dissolved using 1 M NaOH aqueous solution 
(0.5 mL) and wells were washed with 1 M NaOH aqueous solution (0.5 mL). The 
radioactivity of pooled basic fractions was determined using an auto well gamma 
counter. The total cell protein was quantified using a BCA Protein Assay Kit 
following the manufacturer's recommendations and bovine serum albumin as a 
protein standard. All data were expressed as percent dose per microgram protein 
(%dose/µg protein). 
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In blocking experiments, inhibitors (IQP, IIQP, or IB-IQP with final 
concentration 10 µM) in 1 mL of medium without FBS were added to wells containing 
2 x 105 cells/well. After incubation for 10 min, [125I]IIQP or [125I]IB-IQP (3.7 
kBq/well) in 1 mL of medium without FBS was added to each well. Radioactivity and 
protein concentration in cells were determined using the same method above-
mentioned. 
 
2.8. Competitive binding assay using BxPC3-luc cells 
BxPC3-luc cells in RPMI 1640 medium containing 10% FBS and penicillin (100 
IU/mL)-streptomycin (100 µg/mL) were seeded on 96-well plates (containing 5,000 
cells/wells) and incubated for 24 h using a humidified atmosphere (5% CO2) at 37 °C. 
[125I]IIQP and nine concentrations (ranging from 1 pM to 1 mM) of displacing 
nonradiolabeled ligands (IQP, IIQP and IB-IQP) in assay buffer (25 mM HEPES, pH 
adjusted to 7.4) were added. After incubation at 37 °C for 90 min, the cells were 
washed twice with ice-cold PBS (150 µL) to remove the unbound radioligand. The 
cells were dissolved using 1 M NaOH aqueous solution (150 µL) and wells were 
washed with 1 M NaOH aqueous solution (150 µL). The bound radioactivity was 
determined using an auto well gamma counter. IC50 values were calculated by 
GraphPad Prism 5.0 software (La Jolla, CA, USA). 
 
2.9. Animals 
All animal handling procedures were approved by the Kanazawa University 
Animal Care Committee (Permit Number: AP-132633). Experiments with animals 
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were conducted in accordance with the Guidelines for the Care and Use of Laboratory 
Animals of Kanazawa University. The animals were housed with free access to food 
and water at 23 °C with a 12 h light/dark schedule. Six week-old male ddY (27 – 30 
g) and four week-old female BALB/c nu/nu mice (12 – 17 g) were purchased from 
Japan SLC Inc. (Hamamatsu, Japan). For preparing tumor-bearing model, 5 x 106 
BxPC3-luc cells were subcutaneously inoculated into left shoulder of BALB/c nu/nu 
mice. The tumor reached palpable size after 2 weeks of the inoculation. 
 
2.9.1. Biodistribution study 
A saline solution of [125I]IIQP or [125I]IB-IQP (74 kBq, 100 µL) containing 1% 
tween-80 and 10% ethanol was injected intravenously into the tail of the mice. The 
ddY mice were sacrificed at 2, 10 min, 1, 4, and 24 h, meanwhile the tumor-bearing 
mice were sacrificed at 1 h and 4 h ([125I]IIQP ) postinjection. 
For in vivo blocking studies, female BALB/c nu/nu mice were intraperitoneally 
injected with IQP (40 mg/kg) as a blocking agent 1 h prior to intravenously injection 
of [125I]IIQP (37 kBq, 100 µL). The mice were sacrificed at 1 h after administration 
of radiotracer.  
Tissues of interest were removed and weighed. The radioactivity of the tissues 
was determined using an auto well gamma counter, and counts were corrected for 
background radiation. The data were expressed as percent injected dose per gram 
tissue (%ID/g). 
 
2.10. Statistical analysis 
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All data were analyzed using GraphPad Prism 5.0 software and displayed as 
mean ± standard deviation (SD). Significance for in vitro blocking studies was 
calculated using a one-way analysis of variance (ANOVA) followed by Dunnett's post 
hoc test compared to the control group. Significance in cell viability assays was 
determined using ANOVA followed by Tukey’s post hoc test. Significant differences 
of biodistribution in normal mice and tumor-bearing mice between [125I]IIQP and 
[125I]IB-IQP groups were determined using Student's t-test (unpaired, two-tailed). 
Significance for in vivo blocking studies between control and blocking groups were 
calculated using Student's t-test (unpaired, two-tailed). Results were considered 
statistically significant at p < 0.05.  
 
3. Results 
3.1. Synthesis of reference compounds and precursors 
Lead compound 12 (Scheme 1) and the non-radioactive iodinated reference 
compounds, 13 and 18, were easily obtained. Iodine was incorporated to the C-5 of 
quinoline core of IQP using mixture reagents of NCS and NaI with stirring at 50 °C 
for 18 h in acetic acid to obtain compound 13 (Scheme 2). On the other hand, 
compound 18 was synthesized by stirring the mixture of synthesized SIB and IQP at 
50 °C for 2 h in a basic solution (Scheme 3). Retention time for compounds 13 and 
18 on RP-HPLC were 11.7 and 12.5 min, respectively (Supporting Information). For 
synthesis of tin precursor 15, utilizing the Pd(0) catalyst, tri-butyl tin group was 
introduced into IQP instead of iodine in 14 to obtain compound 15 in 48% yield after 
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purification using RP-HPLC. Meanwhile, compound 19 was obtained by the reaction 
between ATE and IQP with 56% yield. 
 
3.2. Cell viability assays 
To assess the binding potential of IIQP and IB-IQP to the ATP-binding site of 
PDGFRβ, TR-PCT1 cells were cultured in the presence of various concentration of 
IQP, IIQP, or IB-IQP (1 – 1000 nM). As displayed in Figure 2, the effects of IB-IQP 
were similar to those of IQP; however, IIQP was more effective than IQP in reducing 
the viability of TR-PCT1 cells.  
 
Figure 2. Cell viability after exposure to IQP, IIQP, and IB-IQP by WST-8 assay. Data are 
presented as mean ± SD for three samples. Significance was determined using a one-way ANOVA 




Two novel 125I labeled IQP, [125I]IIQP and [125I]IB-IQP, were synthesized by an 
iododestannylation reaction with the corresponding tributyltin precursors, as outlined 
in Schemes 2 and 3, respectively. Both these radiotracers were synthesized using NCS 
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as an oxidizing agent in an acidic solution at room temperature in high radiochemical 
yield (95 and 85%, respectively). After purification using RP-HPLC, the 
radiochemical purities were over 99%. 
 
3.4. Partition coefficient 
The n-octanol/PB partition coefficients for [125I]IIQP and [125I]IB-IQP were 2.71 
± 0.03 and 3.19 ± 0.17, respectively. Lipophilicity of [125I]IB-IQP was higher than 
that of [125I]IIQP. 
 
3.5. In vitro stability assay 
The stability of radiotracers in 0.1 M PBS (pH 7.4) was evaluated using TLC 
analysis and confirmed using HPLC. After incubation for 24 h at 37 °C, the purity of 
the radiotracers remained high, and 93.9 ± 0.4% of [125I]IIQP and 94.1 ± 0.7% of 
[125I]IB-IQP remained intact. 
 
3.6. Cell uptake study 
The in vitro cell uptake experiments of [125I]IIQP and [125I]IB-IQP were 
performed using two types of cell lines: PDGFRβ-positive BxPC3-luc cells and 
PDGFRβ-negative MCF7 cells.15,18,40 As shown in Figure 3, BxPC3-luc cells showed 
higher uptake of [125I]IIQP and [125I]IB-IQP then that by MCF7 cells. The uptake of 
[125I]IIQP in BxPC3-luc cells reached 2.34 %dose/µg protein after 4 h incubation, 
whereas that of [125I]IB-IQP reached 0.95 %dose/µg protein. 
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Figure 3. Cellular uptake study. Time-dependent accumulation of (a) [125I]IIQP and (b) 
[125I]IB-IQP in BxPC3-luc (closed circles) and MCF7 (open circles) cells. Data were presented as 
mean ± SD for three samples. 
 
In the blocking studies, the uptakes of [125I]IIQP and [125I]IB-IQP in BxPC3-luc 
cells were significantly reduced by the pretreatment of excess amount of a PDGFRβ 
ligand, IQP, or non-radiolabeled compounds, IIQP or IB-IQP (Figure 4). 
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Figure 4. In vitro blocking study of (a) [125I]IIQP and (b) [125I]IB-IQP in BxPC3-luc cells. 
Data were presented as mean ± SD for three samples. Significance was determined using a one-way 
ANOVA followed by Dunnett's post hoc test (*p < 0.001, vs control [125I]IIQP or [125I]IB-IQP). 
 
3.7. Competitive binding assay using BxPC3-luc cells 
    The competitive binding of [125I]IIQP to BxPC3-luc cells was investigated in the 
presence of PDGFRβ ligand, IQP, IIQP, and IB-IQP. The IC50 values were found to 
be 311 ± 82 nM for IQP, 44 ± 17 nM for IIQP, and 422 ± 54 nM for IB-IQP. 
 
3.8. Biodistribution studies 
Biodistribution of [125I]IIQP and [125I]IB-IQP in normal mice is summarized in 
Table 1. High accumulation of radioactivity after administration in liver, small 
intestine, and large intestine were shown. It was excreted into feces from these tissues 
during 24 h. It indicated that main excretion route of both [125I]IIQP and [125I]IB-IQP 
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was hepatobiliary. It was confirmed that the radioactivity in feces excreted during 24 
h after injection of [125I]IIQP and [125I]IB-IQP (75.93 and 68.75 %ID, respectively) 
were much higher than the radioactivity in urine (3.79 and 13.48 %ID, respectively). 
Additionally, radioactivity was hardly observed in any tissues after 24 h evaluation 
for both radiotracers. 
Biodistribution of [125I]IIQP and [125I]IB-IQP in BxPC3-luc tumor-bearing mice 
is summarized in Table 2. Accumulation of radioactivity in tumor at 1 h postinjection 
of [125I]IIQP (1.29 %ID/gram) was significantly higher than that of [125I]IB-IQP 
(0.52 %ID/gram) in biodistribution experiments using BxPC3-luc tumor-bearing 
mice. Accumulation of radioactivity in tumor at 4 h postinjection of [125I]IIQP was 
0.45 %ID/gram, which was lower than that at 1 h postinjection. 
In in vivo blocking studies, the effect of IQP, a high affinity ligand for PDGFRβ, 
on tumor uptake of [125I]IIQP at 1 h after administration is shown in Figure 5. In this 
case, the radioactivity level in the blood after injection of [125I]IIQP was significantly 
increased by pretreatment of IQP. The values of % injected dose per gram of control 
group and IQP pretreatment group were 0.69 ± 0.10 and 3.16 ± 0.15, respectively. 
Thus, the figures are shown as not only % injected dose per gram but also as tumor / 
blood ratio. The result demonstrated that pretreatment of an excess amount of IQP 
resulted in a significant decrease in tumor uptake and the uptake ratio of tumor to 
blood at 1 h postinjection of [125I]IIQP. 
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Figure 5. Tumor uptake and tumor/blood uptake ratios of [125I]IIQP at 1 h postinjection with 
IQP (40 mg/kg) (blocking group) or control group. Data were presented as means ± SD for three or 
four mice. Significance was determined using an unpaired Student's t-test (*p < 0.05, **p < 0.001). 
 
4. Discussion 
To develop probes for PDGFRβ imaging, the affinity of newly synthesized IQP 
analogs, which contain iodine molecules, for PDGFRβ, was evaluated using WST-8 
assay. WST-8 assay determines cell viability; therefore, it cannot directly be used for 
affinity studies. A negative correlation is speculated between the PDGFRβ-analog 
affinity and TR-PCT1 cell viability because TR-PCT1 cells express PDGFRβ, and 
they die when the receptor signaling pathway is interrupted.41,42 Therefore, WST-8 
assay was used as an index to evaluate affinity changes between the ligand and 
PDGFRβ by introducing an iodine molecule in IQP. IB-IQP and IQP displayed similar 
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affinity for PDGFRβ as a molecular target, whereas IIQP displayed a higher affinity 
than that of IQP (Figure 2). A competitive binding assay was also performed to 
evaluate the affinity of ligands for PDGFRβ. The competitive binding of [125I]IIQP to 
BxPC3-luc cells was investigated in the presence of PDGFRβ ligands, IQP, IIQP, and 
IB-IQP. In this assay, [125I]IIQP do not always bind to only PDGFRβ in tumor cells. 
Thus, the IC50 values of the experiments may not indicate the affinity for PDGFRβ 
completely. However, the IC50 values should be an index of the affinity. As the results, 
the IC50 value of IIQP (44 nM) was lower than those of IQP (311 nM) and IB-IQP 
(422 nM), indicating that IIQP possesses higher affinity than IQP and IB-IQP. It was 
consistent with WST-8 assay. Generally, the introduction of certain molecules, 
functional groups or elements into lead compounds can reduce their affinity for target 
molecules. However, in this study, the introduction of iodine into IQP increased the 
affinity of IIQP for PDGFRβ. This result is extremely favorable for developing 
molecular probes for PDGFRβ imaging.  
Iodogen, chloramine-T (CAT), NCS, and peracetic acid (PAA) are commonly 
used as oxidizing agents for the preparation of radioiodinated compounds. [125I]IIQP 
and [125I]IB-IQP were synthesized using an iododestannylation technique without the 
addition of a carrier and using NCS as an oxidizing agent with excellent 
radiochemical yields. We also tried to synthesize [125I]IIQP and [125I]IB-IQP using 
CAT and PAA as oxidizing agents; however, the radiochemical yields were <50%. 
These results indicated that NCS is the most suitable oxidizing agent for compounds 
with oligo arene, such as IIQP and IB-IQP. 
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In cellular uptake experiments for [125I]IIQP and [125I]IB-IQP, these radiotracers 
showed higher accumulation in PDGFRβ-positive tumor cells (BxPC3-luc) than in 
PDGFRβ-negative tumor cells (MCF7). [125I]IIQP, which had the highest affinity for 
PDGFRβ in the competitive binding assay and WST-8 assay, showed higher 
accumulation in PDGFRβ-positive tumor cells than that of [125I]IB-IQP (Figure 3). In 
in vivo experiments, [125I]IIQP showed significantly higher accumulation in BxPC3-
luc tumor than that of [125I]IB-IQP (Table 2). Moreover, the uptake of [125I]IIQP in 
PDGFRβ-positive tumor cells was inhibited by treatment with an excess amount of 
PDGFRβ ligand both in the cellular uptake study (Figure 4) and in the in vivo blocking 
experiments using tumor-bearing mice (Figure 5). These results indicated that the 
uptake of [125I]IIQP in tumors is PDGFRβ-specific, and it must bind the ATP-binding 
site of PDGFRβ in the tumor cell. 
Small molecule TKIs, including [125I]IIQP and [125I]IB-IQP, target the 
intracellular domain of RTKs, and for this binding, they should diffuse through the 
cellular membrane. The log P values of the compounds are an important factor to 
penetrate the cellular membrane. It has been shown that a log P value of 1 to 3.5 is 
required to passively penetrate cellular membrane.43-46 In this study, Log P values of 
[125I]IIQP and [125I]IB-IQP were 2.71 and 3.19, respectively. This suggested that the 
lipophilicity of both the radiotracers was suitable for them to be used as PDGFRβ 
imaging probes. 
In the biodistribution experiments, [125I]IIQP and [125I]IB-IQP were mainly 
excreted through the hepatobiliary pathway, which is often observed for small 
molecule radiotracers directed to the ATP-binding site of TKs.20,23,47,48 This excretion 
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route may be due to the moderately high lipophilicities of these radiotracers. 
Meanwhile, it has been known that free iodine accumulates in the stomach and 
thyroid; this is used as an index of deiodination of radioiodine-labeled tracers in vivo. 
In this study, the accumulation in the stomach was not high, suggesting that both 
[125I]IIQP and [125I]IB-IQP are highly stable not only in vitro but also in vivo. In the 
case of [125I]IIQP, the biodistribution study in tumor-bearing mice at 4 h postinjection 
was performed because we expected more effective tumor detection derived from 
higher accumulation ratios of tumor / non-target tissues. The results showed that the 
tumor accumulation decreased; however, tumor to blood and tumor to muscle ratios 
at 4 h postinjection were higher than those at 1 h postinjection because radioactivity 
in the blood and muscle was prominently decreased. Many studies have reported that 
P glycoprotein (P-gp), breast cancer resistant protein (BCRP), and/or other drug 
efflux transporters can hinder tumor uptake of anticancer drugs.49,50 Planar structure, 
high lipophilicity, and neutral or positive charges are some of requirements for P-gp 
substrates.51 Because [125I]IIQP possesses these characteristics, it can be a substrate 
for P-gp and therefore, its accumulation may have decreased in tumor cells. However, 
further research is warranted to prove whether [125I]IIQP is a P-gp substrate. Another 
possibility is the presence of radioactive metabolites that have less or no affinity to 
the molecular target. Rapid metabolism leads to the loss of affinity for target 
molecules and resulting low tumor uptake.52 Although [125I]IIQP showed high 
stability both in vitro and in vivo, this possibility cannot be completely excluded 
because we did not perform a metabolic study. 
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5. Conclusion  
In this study, we synthesized the radiolabeled compounds [125I]IIQP and [125I]IB-
IQP using an iododestannylation reaction under non-carrier added condition with high 
radiochemical yields and high purities. This method can also be used to synthesize 
other radioiodinated compounds containing quinoline-benzimidazole derivatives. 
The present study showed that radioiodinated IIQP could be a promising imaging 
agent compared with radioiodinated IB-IQP. However, modification of its structure 
may be needed to obtain appropriate PDGFRβ-targeted imaging agents, which have 
higher tumor uptake and tumor to background ratios. 
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Table 1. Biodistribution of [125I]IIQP and [125I]IB-IQP at 2, 10 min, 1, 4, and 24 h after i.v. injection 
in ddY mice. 
Tissues Time after injection 


















































































































































































































































































Data were presented as %injected dose / gram tissue. Each value represent mean ± SD for three or 
four mice. Significance was determined using an unpaired Student's t-test (*p < 0.05, **p < 0.01 vs. 
[125I]IIQP).  
† presented as %ID/organ. 
Effendi el al. 35/35 
Table 2. Biodistribution of [125I]IIQP and [125I]IB-IQP at 1 h and 4 h after i.v. injection in BxPC3-
luc tumor-bearing mice. 
Data were presented as means ± SD of %injected dose / gram of tissue for three or four mice. 
Significance was determined using an unpaired Student's t-test (*p < 0.05, **p < 0.01 vs. [125I]IIQP).  
† presented as %ID/organ. 
 
Tissues [125I]IIQP [125I]IB-IQP  
1 h 4 h 1 h  
Blood 
Liver 
Kidney 
Small intestine 
Large intestine 
Spleen 
Pancreas 
Lung 
Heart 
Stomach† 
Bone 
Muscle 
Brain 
BxPC3-luc tumor 
0.69 (0.10) 
11.10 (2.64) 
15.60 (2.05) 
37.37 (3.11) 
3.98 (1.35) 
3.46 (0.45) 
7.67 (2.50) 
12.28 (0.94) 
1.37 (0.13) 
2.99 (1.09) 
1.37 (0.13) 
1.14 (0.25) 
0.14 (0.02) 
1.29 (0.43) 
0.15 (0.01) 
1.48 (0.10) 
2.65 (0.37) 
3.98 (0.44) 
22.09 (2.87) 
0.35 (0.09) 
2.20 (0.20) 
2.73 (0.44) 
0.29 (0.07) 
0.20 (0.03) 
0.03 (0.05) 
0.13 (0.01) 
0.03 (0.00) 
0.45 (0.04) 
0.23 (0.03) 
4.81 (0.66) 
1.13 (0.09) 
45.53 (2.53) 
7.88 (3.74) 
0.61 (0.06) 
1.23 (0.16) 
1.16 (0.23) 
0.44 (0.02) 
0.26 (0.06) 
0.29 (0.03) 
0.38 (0.03) 
0.05 (0.00) 
0.52 (0.09) 
** 
* 
** 
* 
 
** 
* 
** 
** 
* 
** 
** 
** 
* 
